Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      Cabanillas, Maria E; Schlumberger, Martin; Jarzab, Barbara; Martins, Renato G; Pacini, Furio; Robinson, Bruce; Mccaffrey, Judith C; Shah, Manisha H; Bodenner, Donald L; Topliss, Duncan; Andresen, Corina; O'Brien, James P; Ren, Min; Funahashi, Yasuhiro; Allison, Roger; Elisei, Rossella; Newbold, Kate; Licitra, Lisa F; Sherman, Steven I; Ball, Douglas W.
    • الموضوع:
      2015
    • Collection:
      Università degli Studi di Siena: USiena air
    • نبذة مختصرة :
      Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor of the vascular endothelial growth factor receptors 1 through 3 (VEGFR1-VEGFR3), fibroblast growth factor receptors 1 through 4 (FGFR1-FGFR4), platelet-derived growth factor receptor α (PDGFRα), ret proto-oncogene (RET), and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling networks implicated in tumor angiogenesis. Positive phase 1 results in solid tumors prompted a phase 2 trial in patients with advanced, radioiodine-refractory, differentiated thyroid cancer (RR-DTC).
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/25913680; info:eu-repo/semantics/altIdentifier/wos/WOS:000359190400015; volume:121; issue:16; firstpage:2749; lastpage:2756; numberofpages:8; journal:CANCER; http://hdl.handle.net/11365/1011398; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84938744059
    • الرقم المعرف:
      10.1002/cncr.29395
    • Rights:
      info:eu-repo/semantics/openAccess
    • الرقم المعرف:
      edsbas.CE9B32EE